Pfizer, BioNTech's Omicron-Adapted Covid-19 Vaccine Gets E.U. Marketing Recommendation
By Michael Susin
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is one step closer to becoming available across the European Union.
The drugmakers said the recommendation will be reviewed by the European Commission which is expected to make a final decision soon.
The recommendation from the Committee for Medicinal Products for Human Use applies for the Omicron KP.2-adapted monovalent Covid-19 vaccine for active immunization in individuals six months of age and older.
If approved, the vaccine will be available based on individual country government requests and national recommendations of the block.
This could be the companies' second Omicron-related vaccine authorized in the European Union. In July 2024, the European Commission granted marketing authorization for Pfizer and BioNTech's Omicron JN.1-adapted Covid-19 vaccine.
The Omicron KP.2-adapted vaccine was approved for use in the U.S on individuals 12 years of age and older, and granted emergency use authorization for individuals six months through 11 years of age on Aug. 22.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 20, 2024 09:06 ET (13:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks